A combination of the marijuana components THC and CBD leads to a significant and sustained reduction in agitation in the vast majority of people with Alzheimer’s disease of other forms of dementia, according to a new federally funded study.
The placebo-controlled, double-blind trial involved a cannabis preparation called T2:C100 that contained 2mg THC and 100mg CBD, and included 120 people with dementia who were eligible to receive hospice care and were experiencing clinically significant agitation.
The researchers, from Medical University of South Carolina and Georgetown University, found that there was a “statistically significant improvement” in scores on a standardized scale to systematically assess agitation among patients who received the cannabis medication as compared to the placebo group—measured at both two weeks into the trial and at the end of the full 12-week study.
After week two, 84 percent of participants receiving THC and CBD improved, according to the caregiver-rated scale, compared to 31 percent of those who got the placebo. After the full trial, 87 percent of those who got the cannabis medication manufactured by MediPharm Labs saw improvement, as compared to 24 percent in the placebo group.
The results, presented at the Alzheimer’s Association International Conference this month, suggest
Read full article on Marijuana Moment
